Association of serum digoxin concentration with morbidity and mortality in patients with atrial fibrillation, heart failure and reduced ejection fraction of 45 % or below

Degradation of the α-Carboxyl Terminus 11 Peptide: In Vivo and Ex Vivo Impacts of Time, Temperature, Inhibitors, and Gender in Rat

“…Presently, there are no curative approaches to treat patients with MI and/or HF . In the clinical management of acute MI, immediate treatments include the administration of antithrombotic drugs (e.g., heparin), blood thinners (e.g., aspirin), or the reopening of blocked coronary arteries (e.g., via angioplasty and stent placement). , During the late stage of acute MI and HF, the primary treatment is to relieve patient symptoms, increase survival rate, and improve quality of life via administration of various drugs [e.g., classical angiotensin-converting enzyme (ACE) inhibitors, β blockers, diuretics, and digoxin]. Even though these drugs are available to most patients, they are not a curative solution and do not completely restore heart function.…”